PRESS RELEASE
For immediate release

Ticker Symbol: CUR

DIAGNOCURE ANNOUNCES 2005 SECOND QUARTER RESULTS

QUEBEC CITY (June 7, 2005) – DiagnoCure Inc. (TSX: CUR), a leading developer and provider of innovative high-value cell-based assays and molecular diagnostics for the early detection of cancers, today announced its financial results for the second quarter ended April 30, 2005.

Results for the Second Quarter of 2005

Total revenues for the second quarter of 2005 were $1,960,312, an increase of 22% when compared with $1,608,982 for the second quarter of 2004. About $1 million of that revenue was generated by the continuing payments to DiagnoCure from Gen-Probe related to the License, Development and Cooperation Agreement for the PCA3 technology. Products sales were $749,842 for the second quarter of 2005 up 61% from $465,083 for the same period a year ago.

Operating expenses and cost of sales for the quarter were $2,587,171 up $807,819 from $1,779,352 for the same quarter in 2004. This increase is due to acceleration in the general overall operating, investment and product development activity of the Company including an increase in net research and development expenses of $292,711. Net loss for the second quarter of 2005 was $626,859, or $0.02 per share, compared with a net loss of $170,370 or $0.01 per share, for the second quarter of 2004. For the second quarter of 2005 the stock-based compensation (a non-cash item) was $268,691 and represented 43 % of the total net loss. For the first six-months in 2005 the net loss was $1,234,466 or $0.04 per share, compared with $568,469 or $0.02 per share a year ago. For the same period in 2005 the stock-based compensation was $601,254, which represented 49 % of the total net loss.

Total revenues for the six-month period ended April 30, 2005 were $3,743,564 up 34% when compared with $2,780,703 for the same period of 2004.

"We continue to be very pleased with DiagnoCure's growth and results, which are in line with Management's expectations," said Pierre Desy, President & CEO. "We are delivering on our commitments, the Gen-Probe relationship continues to generate additional cash flow and earnings and their commercialization efforts for the ASR version of the PCA3 assay are on track for delivery by year-end."

At the end of the second quarter, cash, short-term and long-term investments stood at $25,356,069 compared to $5,748,639 at the end of the second quarter of 2004. Management is satisfied that it has adequate cash resources to execute its current business plan.

Highlights of the Quarter

During the quarter, DiagnoCure announced the promising results of three studies on the company's PCA3 gene. Specifically, one study demonstrated that Gen-probe's prototype assay was able to detect prostate cells in 100 % of samples tested after an attentive digital rectal exam (DRE), which was more favorable than the 82 % of samples after DRE with DiagnoCure's original uPM3 assay. The APTIMA assay also yielded informative results on 90% of samples collected before the DRE. The second important finding was that the prototype assay yielded a sensitivity of 66 % and a specificity of 75 % without centrifuging samples, a significant improvement over the standard PSA test, which in the same study demonstrated only a specificity of 19 %. Among the negative patients were 27 with PIN (Prostatic Intraepithelial Neoplasia) or ASAP (Atypia Suspicious of Adenocarcinoma of the Prostate) lesions thought to be pre-cancerous being associated with the finding of cancer in subsequent biopsies up to 50 % of the time.

A more recent study presented by Dr. Jack Schalken at the recent American Urology Association conference demonstrated the potential diagnostic value of the PCA3 gene with 67 % sensitivity, 83 % specificity and a 90 % negative predicative value utilizing a rtPCR-based research assay for the gene. More significantly, it demonstrated a potential prognostic value by demonstrating in 49 men with cancer that the quantitative expression of the PCA3 gene correlated with the cancer's Gleason score, the most widely accepted measure of tumor aggressiveness.

Other recent events included the appointment of Mr. Paul Gobeil, FCA as Chairman of the Board and Mr. Thom Skinner, CA as Chief Financial Officer for the Company. In April, the Company was pleased to receive the 2005 Genesis Award for Entrepreneurship having demonstrated a superior rate of growth and achievement of outstanding results in effective management of its alliances, financial capabilities and research teams. During the quarter, DiagnoCure also welcomed Kaplan Ltd. STL and MM France to its growing list of international distributors, now offering, in France, Algeria, Tunisia, Morocco, Turkey and Libya, our uCyt+™ test for monitoring recurrent bladder cancer.

Interest in DiagnoCure and its prospects continues to build among the investment community and analysts. After the quarter's end, two more securities firms, Orion Securities Inc. and CTI Capital Inc. initiated coverage on DiagnoCure by issuing research reports. This brings to a total of four the number of analysts that now cover the company.

Finally, the United States Patent and Trademark Office granted the first patent relating to the PCA3 gene technology. Specifically, the patent primarily deals with the promoter region of the PCA3 gene that may be useful in the development of a therapeutic application of this highly prostate cancer-specific gene.

Financial Data

For the periods of	Three-month ended April 30		Six-month ended April 30	
	2005	**2004**	**2005**	2004
Sales	**749,842**	465,083	**1,283,001**	673,174
Revenue under research and license agreement	**995,581**	1,104,211	**2,039,327**	2,026,183
Interest	**214,889**	39,688	**421,236**	81,346
Total revenues	**1,960,312**	1,608,982	**3,743,564**	2,780,703
Cost of sales	**588,171**	297,803	**928,824**	504,259
Gross margin	**1,372,141**	1,311,179	**2,814,740**	2,276,444
Operating expenses*	**1,999,000**	1,481,549	**4,049,206**	2,844,913
Net loss *	**(626,859)**	(170,370)	**(1,234,466)**	(568,469)
Diluted net loss per share	**(0.02)**	(0.01)	**(0.04)**	(0.02)
Weighted average number of common shares outstanding	**34,193,809**	29,136,089	**34,192,102**	29,107,526
**Includes non-cash expense adjustment for stock-based compensation*	***268,691***	*181,434*	***601,254***	*258,066*

Consolidated Balance Sheets

	As at April 30	
	2005	2004
Cash, cash equivalents, temporary and long-term investments	**25,356,069**	5,748,639
Total assets	**27,905,329**	7,669,172
Shareholders' equity	**26,259,579**	4,527,169

About DiagnoCure

DiagnoCure specializes in the development, production and commercialization of diagnostic tests for the early detection of cancers. DiagnoCure's first product, ImmunoCyt™ /uCyt+™, is an important tool for the diagnosis and monitoring of bladder cancer. In 2003, the Company completed the development of uPM3™, a non-invasive test for the early detection of prostate cancer. In November 2003, DiagnoCure granted an exclusive worldwide license for the use of the PCA3 technology in prostate cancer diagnosis to Gen-Probe (NASDAQ: GPRO). In March 2004, the company launched Odyssee™, an automated microscopy workstation that screens, performs image analysis, reports and archives data and images. After successfully completing a lung cancer pilot study, DiagnoCure is developing a first generation molecular assay and intends to undertake a multi-center clinical trial in 2005. The Company is continuing the validation of markers for integration into a prototype test for the early detection of kidney cancer. DiagnoCure is headquartered in Quebec City, Canada. Additional information can be found at www.diagnocure.com.

Forward-looking statements

Certain statements in this release are forward-looking. These statements are based on DiagnoCure's current expectations and involve many risks and uncertainties. DiagnoCure undertakes no obligation to publicly update or revise any forward-looking statements contained herein.

Contact : **DiagnoCure Inc.**
Romano Robusto
Director, Legal Affairs and Communications
(418) 527-6100 e-mail: communications@diagnocure.com